Both schedules of imatinib have acceptable toxicity and facilitate SCT in CR1 in the majority of patients, but concurrent administration of imatinib and chemotherapy has greater antileukemic efficacy.
only.
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INTRODUCTION
Adult patients with Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) have a significantly inferior treatment outcome than patients who are Ph negative. [1] [2] [3] [4] [5] This is partly due to a lower complete remission rate following induction chemotherapy but more importantly to a significantly shorter remission duration, which ranges from 9-16 months. Intensification of chemotherapy failed to improve overall treatment results despite CR rates of up to 90%. 5 As the probability of long-term survival with chemotherapy alone is less than 10%, allogeneic stem cell transplantation (SCT) in first complete remission (CR1) is generally accepted as the treatment of choice. [6] [7] [8] [9] [10] [11] However, only 20-60% of patients actually undergo alloSCT in large prospective studies. Moreover, even after allogeneic SCT in CR1 the probability of relapse for Ph+ALL patients is approximately 30%, which together with a high transplant-related mortality of 20-40% highlights the limitations of current therapy. [12] [13] In childhood ALL, the level of residual disease that is still detectable prior to transplant correlates with outcome after SCT. [14] [15] Thus, treatment approaches that enhance the anti-leukemic efficacy without incurring excessive toxicity prior to transplantation may lead to improved overall outcome.
The ABL tyrosine kinase inhibitor imatinib (Glivec, Gleevec) selectively targets the molecular mechanism underlying Ph positive leukemias 16 and was shown in early phase I and II studies to have significant, albeit non-sustained activity against relapsed or refractory Ph+ALL. [17] [18] [19] Based on the premise that imatinib would be more effective during first-line as opposed to salvage treatment of Ph+ALL, entailing a lower incidence of resistance, the clinical value of imatinib in newly diagnosed
Ph+ALL has received increasing attention. Preclinical in vitro data suggest that imatinib may augment the activity of cytotoxic drugs commonly used in treatment of only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From ALL and CML. [20] [21] [22] In the clinical setting, the potential of combination therapy to either enhance treatment efficacy or potentially aggravate therapy-associated toxicity prompted several ALL study groups to explore different schedules of imatinib in conjunction with a variety of chemotherapy regimens. [23] [24] [25] [26] Together, these studies
show that incorporation of imatinib in the first-line treatment of adult Ph+ALL is associated with a hematologic CR rate consistently above 90%, irrespective of the schedule with which imatinib and chemotherapy were administered. While the results of these studies compare favorably with the 70%-90% CR rate generally achieved by the respective chemotherapy regimens alone, it is unclear whether concurrent or alternating schedules of imatinib and cytotoxic drugs differ in their relative efficacy and tolerability. Moreover, it is noteworthy that induction with imatinib monotherapy likewise results in CR rates of approximately 95%, identical to combination therapy but not associated with toxicity of chemotherapy. [27] [28] Thus, it has not yet been established how imatinib is best incorporated in the front-line treatment of Ph+ALL.
Here, we report the results of a prospective, multicenter clinical trial encompassing 92 patients with newly diagnosed Ph+ALL who received uniform induction and consolidation chemotherapy in conjunction with one of two schedules of imatinib that were investigated sequentially: while imatinib was administered alternating with the chemotherapy cycles in the first patient cohort, the second treatment schedule in which imatinib was administered concomitantly throughout induction phase 2 (INDII), first consolidation (C1) and up to SCT was introduced by amendment after sufficient safety and efficacy data were available from cohort 1. Besides assessing feasibility and toxicity, we compared the anti-leukemic activity of these two schedules in terms of CR rate, incidence of relapse prior to SCT, proportion of patients transferred to SCT, frequency of PCR negativity, and BCR-ABL transcript levels (minimal residual only.
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PATIENTS AND METHODS

Patients
Patients older than 18 years with newly diagnosed Ph+ALL or CML lymphoid blast crisis were eligible if they had an ECOG performance status of 0-2, adequate organ function, no life-threatening or uncontrolled infections, and had received no other therapy than specified by GMALL protocols 06/99 or 07/03 (Table 1) . These protocols differed slightly only with respect to the dexamethasone dose during prephase and INDI and the timing of asparaginase during INDI. All patients gave written informed consent to participate in the study, and the study was reviewed and approved by a recognized ethics review committee at each trial center. The study was performed in accordance with the Declaration of Helsinki, as amended in Tokyo, Venice and Hong Kong.
Study Design
This prospective, multicenter phase II study investigated the safety and efficacy of imatinib given in conjunction with induction and early consolidation chemotherapy in adult Ph+ALL. The overall design of the schedules is depicted in Figure 1 , the individual components of chemotherapy are listed in Table 1 Figure 1 ).
The initial starting dose of imatinib with the alternating schedule was 400mg, given orally as a single daily dose (n=35); this was increased to 600mg QD (n=12) by protocol amendment after the availability of sufficient safety data. In cohort 2, imatinib was started at 600mg QD. Imatinib was interrupted in the event of grade 3 or 4 nonhematologic toxicity until toxicity resolved to grade 1 or less and was then resumed at a reduced dose of 300mg or 400mg, depending on the starting dose. In the first cohort, imatinib was interrupted for grade III or IV neutropenia or thrombocytopenia and resumed after recovery of PB values to cytopenia grade I. In patients who received imatinib concurrently with chemotherapy (cohort 2) and experienced grade III or IV hematologic toxicity, imatinib was interrupted only when the duration of severe cytopenia was felt by the investigator to exceed the duration expected from chemotherapy alone, as prolonged cytopenias occur in a significant proportion of patients during remission induction. 29 No dose-reduction was scheduled for anemia, except for gade 3 or 4 anemia resulting from an acute cause considered to be related to administration of imatinib, e.g. gastrointestinal hemorrhage. 
Response criteria
Complete remission (CR) was defined as less than 5% blasts in a bone marrow of normal cellularity with an ANC of greater than 1.5x10 9 /L and platelet counts greater than 100x10 9 /L. A partial response (PR) required a response of the leukemic cells as only.
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For a molecular CR, qRT-PCR negativity with a PCR run of adequate sensitivity was required in conjunction with a hematologic CR. Unless indicated otherwise, negative qRT-PCR were confirmed by a nested PCR approach as previously descibed.
31-32
Statistical analysis
Differences in BCR-ABL transcript levels in patients from the same cohort were assessed by the Wilcoxon test, the Mann-Whitney test was applied to comparisons of BCR-ABL levels between patients cohorts. The proportion of patients with a given characteristic was compared by means of Fisher´s exact test. Remission duration and overall survival curves were plotted according to the methods of Kaplan-Meier, with differences between patient groups analyzed by the log rank test.
RESULTS
Patients
A total of 92 patients were enrolled, 47 in the alternating schedule cohort and 45 in the cohort receiving imatinib and chemotherapy in parallel ( Figure 1 and 2B) and therefore by their pre-study response to weeks 1-3 of induction chemotherapy (INDI): 78% of patients in the alternating cohort but only 56% in the parallel treatment cohort were in CR after INDI ( Fig. 2A and 2B ). In the latter cohort 43% (19/44) of patients were non-responders or had achieved only a PR at the time of enrollment (Fig. 2B ). Thus, a higher proportion of patients in the concurrent than in the alternating treatment cohort displayed up-front resistance to chemotherapy alone (p=0.06).
Alternating schedule -feasibility and outcome
Given the requirement for recovery of PB values before study entry, imatinib was started a median of 19 days (range 5-52 days) after INDII, and was administered for a median of 28 days (range 14-64 days; 25% and 75% percentile 28 days and 28.5 days, respectively). Median ANC and platelet counts during the 4 week postinduction imatinib cycle decreased by 22.6% (from 3.1x10 9 /L to 2.5x10 9 /L) and 33.7%
(from 264x10 9 /L to 175x10 9 /L), respectively. No grade III or IV hematologic toxicities or infectious or bleeding complications were recorded during this imatinib cycle. Five patients received fewer than the scheduled 28 days imatinib: one patient discontinued imatinib after 2 weeks subsequent to withdrawing consent for all antileukemic therapy; in four patients interruption or early termination of imatinib because of grade 3 myalgia (n=1), grade 2 facial edema (n=1) and grade 3 nausea resulted in treatment durations of 25 days (n=2) and 27 days (n=2), respectively. When dose reductions and days of imatinib actually delivered were considered together, 36 of only.
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As only patients already in CR were eligible for study entry in this cohort, efficacy was assessed primarily at the molecular level by analysis of BCR-ABL transcript levels (see below). Nevertheless, all 3 patients who entered the study with a PR achieved a CR after the first 28-day cycle of imatinib. Moreover, no patient relapsed during the post-induction imatinib cycle.
The treatment course is depicted in Figure 2A . Thirty-seven patients (79%) received consolidation (C1), with a median interval of 5 days (range 1-16 days) from stopping imatinib, 10 patients were transferred to SCT by center decision instead of receiving C1. There was one septic death during cytopenia after C1, the other patients recovered without unexpected toxicity. Twenty-five of the 36 patients who completed C1 (69%) received a second imatinib cycle, with a median duration of 41 days (range 10-68 days).
Overall, 40 of the 45 patients from this cohort who were considered eligible for SCT underwent allogeneic (n=36) or autologous (n=4) SCT in CR1, for an overall transplantation frequency of 85%. The median time from diagnosis to SCT was 165 days (range 103-287 days). Three patients relapsed while receiving imatinib after C1, i.e. prior to planned SCT ( Fig. 2A) , with a remission duration of 4.9-6.2 months. Two elderly patients who were ineligible for SCT relapsed 7.6 and 12 months after imatinib was discontinued; the remission duration was 8.6 and 14.4 months. One patient withdrew consent after C1 and relapsed 6.4 months after imatinib was discontinued.
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Concurrent schedule -hematologic response
As described above, 43% of patients in the concurrent cohort had not achieved a CR after INDI ( Figure 2B ). All 10 PR patients and 8 of 9 non-responders after INDI subsequently achieved a CR with concurrent administration of INDII and imatinib.
One patient with primary refractory leukemia after INDI did not respond to coadministration of imatinib and INDII and was taken off study; a subsequent salvage attempt with C1-based chemotherapy plus imatinib was unsuccessful. All 25 CR patients maintained their response after INDII, resulting in an overall CR rate of 95.6% (43 of 45 patients; not evaluable for response: n=1) (Fig. 2B) . Prolonged pancytopenia developed after INDII in one patient, leading to removal from the study.
Three patients withdrew consent before receiving post IND imatinib (n=2) and prior to C1 (n=1), respectively, None of the 40 patients who remained on study relapsed or died prior to consolidation C1 (n=26) or SCT that was performed instead of C1 (n=14), respectively ( Figure 2B ). Twenty-six patients (55.6%) received C1 in conjunction with imatinib, 12 of whom continued imatinib after C1 until allogeneic SCT. One patient relapsed before SCT could be performed, 9 days after discontinuation of imatinib.
Eighty percent (36/45) of patients were transferred to SCT in CR1. This was not significantly different from the transplantation frequency (85%) in the alternating treatment cohort ( Fig. 2A and 2B ). Median time from diagnosis to SCT was also similar (136 days, range 90 to 193 days).
Concurrent schedule -feasibility and tolerability
Median duration of imatinib treatment from start of INDII to C1 was 78 days (range 8-138 days; evaluable n=35). Imatinib was initiated at 600mg once daily (QD) 
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With both schedules, the 4-week post-induction imatinib cycle was associated with an additional, approximately 1 log decrease of bcr/abl transcript levels assessed prior to C1 (p=0.3) (Fig. 3) . Notably, the proportion of patients in whom BCR-ABL transcripts became undetectable prior to C1 increased to 52% in the concurrent treatment cohort but did not increase further in the alternating treatment group (19%) (Fig. 4) . This difference in PCR negativity achieved with the two treatment schedules is significant (p=0.01).
Molecular response in relation to hematologic response after IND I
Whereas early phase 1 and 2 studies showed that single-agent imatinib induced a CR in approximately 20% of Ph+ALL patients who failed chemotherapy, a CR rate exceeding 90% has been reported in response to imatinib in patients with newly diagnosed Ph+ALL. 27, 28 We therefore examined whether the quality of the molecular response to concurrent imatinib and INDII differed by the hematologic response to weeks 1-3 of INDI. As expected, pre-study BCR-ABL transcript levels were higher in patients with a poor response to INDI (PR and non-response, n=15) than in patients who had achieved a CR (n=21) (median: 7.6x10 -3 vs. 5x10 -5 ; p=0.0001)( Figure 5 ). 
Treatment outcome by schedule
To determine whether the imatinib schedule had an impact on treatment outcome, we compared remission duration and overall survival of the two cohorts by Kaplan Meier analysis ( Figures 6 A and B) . In both patient cohorts, median remission duration is as yet undefined. The estimated probability of remission 12 months and 24 months after first documented CR was 65%+8% and 52%+9% with the alternating schedule and 71%+8.5% and 61%+10% with the concurrent schedule (p=0.83).
Median survival of patients treated according to the alternating and concurrent schedules was 16.3 months and 19.6 months, respectively. By Kaplan-Meier analysis, the estimated probability of survival 12 months and 24 months after diagnosis was 72%+6.5% and 36.2%+7% with the alternating schedule and 61%+8% and 43%+9% with the concurrent schedule (p=0.97).
DISCUSSION
Recent clinical trials employing different schedules of chemotherapy and imatinib in patients with newly diagnosed Ph+ALL have demonstrated higher CR rates than in
historical cohorts treated with induction chemotherapy alone. [23] [24] [25] [26] However, it has not been established how to best schedule imatinib in relation to chemotherapy during first-line treatment of Ph+ALL. We therefore prospectively investigated the tolerability and anti-leukemic efficacy of two treatment strategies in which imatinib was combined with remission induction and consolidation chemotherapy using either an only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From alternating or a concurrent application schedule. Since safety data addressing the potential of imatinib to aggravate chemotherapy-related toxicity were lacking when the clinical trial was first initiated, the first patient cohort to be investigated received chemotherapy and imatinib sequentially. We demonstrate that administration of imatinib for 28 days following remission induction chemotherapy is feasible and safe, with essentially no severe imatinib-related hematologic or non-hematologic toxicity. 31 Surprisingly, we also found that the molecular response to first-line imatinib in this cohort of chemosensitive patients was not superior to the 1.37 log reduction of the BCR-ABL/GAPDH ratio that we previously observed in 56 patients with relapsed or refractory Ph+ALL after 4 weeks of imatinib given at the same dose levels (400-600mg). 32 A possible explanation for this lower than expected molecular response is a lower sensitivity to imatinib in the subpopulation of leukemic cells that persists after chemotherapy. Alternatively, the administration of cytotoxic agents prior to imatinib may induce imatinib-resistance, e.g. by upregulation of cellular drug efflux pumps such as MDR1/ABCB1 34, 35 or (BCRP)/ABCG2. 36 Conceivably, a better molecular response could have been achieved by extending the duration of imatinib beyond 4 weeks, as we previously showed that the median time to best BM response only.
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After demonstrating good tolerability but a suboptimal molecular response with the alternating schedule, we examined whether the antileukemic efficacy of imatinibbased induction therapy was more pronounced when imatinib was administered concurrently with the same induction and consolidation chemotherapy as in the first cohort. Patients were enrolled after the first 3 weeks of induction chemotherapy rather than immediately after diagnosis to avoid delaying treatment while awaiting clarification of the patients´ BCR-ABL status in this multicenter setting. In contrast to the cohort receiving the alternating schedule, patients were also eligible if they had not achieved a CR after INDI. Due to this change of eligibility criteria, a higher proportion of patients with an unfavorable prognosis was treated according to the concurrent schedule; this imbalance was in our view justified by a less than 20%
probability that non-responders to INDI would achieve a CR after completing induction chemotherapy alone.
Our study clearly demonstrates that the simultaneous administration of imatinib and induction and consolidation chemotherapy is highly effective first-line treatment for adult Ph+ALL, with a CR rate of 95%. PCR negativity was achieved in 50% of patients. Overall, these data are consistent with the hematologic and molecular remission rates reported in two smaller studies that examined the use of imatinib and chemotherapy in first-line therapy of adult Ph+ALL. Thomas In an interim analysis of 24 patients, the CR rate attained after a single induction cycle was 96%. PCR negativity, though not confirmed by nested-PCR, was achieved in 50% of patients on day 63, prior to first consolidation. These results correspond well with the 52% incidence of PCR negativity that we observed in the 45 patients receiving concurrent imatinib and chemotherapy, whereas sequential treatment with chemotherapy and imatinib (alternating cohort, n=47) resulted in a molecular remission rate prior to consolidation of only 19%. These differences between the JALSG and our study may be due to the more stringent criteria for PCR negativity in our study, which required confirmation by nested-PCR. Differences in the chemotherapy regimens also need consideration, although the GMALL induction regimen is more intensive, which is difficult to reconcile with an inferior response unless the cytotoxic drugs reduce the sensitivity to imatinib, as discussed previously.
Remarkably, hematologic as well as molecular responses in the concurrent cohort of our study were independent of the remission status after the first 3 weeks of chemotherapy. Patients who were refractory and those in CR after INDI did not differ significantly in terms of their probability of achieving either a hematologic or a molecular remission. In view of the 17-30% CR rates with imatinib monotherapy in Ph+ALL patients failing chemotherapy in the initial phase I and II studies, [17] [18] [19] these results are most likely attributable to synergy between imatinib and the cytotoxic only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From agents used in our induction regimen rather than to the difference in cumulative dose of imatinib, although this cannot be unequivocally proven given the design of our study. In agreement with our data, Thomas et al. reported that 4 patients with refractory Ph+ALL achieved a CR after receiving imatinib in combination with one cycle of chemotherapy according to the hyper-CVAD regimen. 23 These observations are also consistent with preclinical data showing additive or even synergistic effects when imatinib is combined with cytotoxic agents. [20] [21] [22] Further clinical support for the superior antileukemic efficacy of the concurrent as opposed to the alternating schedule stems from our data showing that a significantly higher percentage of patients converted to PCR negativity, despite a higher proportion of patients with adverse clinical risk features in this cohort. Also, no patient in the concurrent treatment cohort relapsed on study, in contrast to 3 patients receiving the alternating schedule, although this difference was not statistically significant. Interestingly, the greatest differential effect of schedule on the molecular response became apparent only after the 4 week imatinib cycle that was administered between INDII and C1, with PCR negativity developing in 52% and For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From patients treated according to the concurrent and the alternating schedules; this indicates that the severe adverse events were attributable primarily to chemotherapy, and/or that imatinib-related toxicity was transient. The incidence of non-hematologic toxicities in the JALSG study with a primarily alternating schedule of chemotherapy and imatinib and the MDACC study with a parallel schedule were both acceptable, with infections and febrile neutropenia being the predominant grade 3 or 4 toxicities. 23, 24 Conspicuously, we observed in our study a significantly higher rate of Currently, allogeneic SCT is thought to be the only curative therapy for Ph+ALL in adults, with transplantation in CR1 yielding the by far best results. [6] [7] [8] [9] [10] [11] With both of our treatment schedules, overall transplantation frequencies in CR1 (80-85%) and the proportion of patients undergoing allogeneic SCT (77%) were comparable. This allogeneic transplantation rate is considerably higher than the approximately 50% previously reported by the LALA and GMALL multicenter cooperative group trials which did not incorporate imatinib as an element of first-line treatment (reference 33 and data not shown). It can be attributed to a low relapse rate and acceptable toxicity in each of the two treatment regimens examined. Similarly high transplantation frequencies were recently reported by Lee et al. 31 from a single-center study employing a similar schedule of imatinib and chemotherapy as in our study, and in only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From the study from the JALSG, in which 15 of 24 patients (63%) underwent alloSCT in CR1. 24 In children, the level of residual disease prior to SCT has been shown to correlate with long-term outcome. [14] [15] Similarly, in an analysis of patients treated in the LALA-94 trial who were eligible for SCT, Dombret et al. reported superior treatment outcome in the subgroup who had achieved BCR-ABL negativity after two chemotherapy cycles when compared to patients who remained BCR-ABL positive by PCR. 4 While the percentage of patients undergoing SCT in our study was uniformly high, the proportion of patients achieving PCR-negativity clearly favored the concurrent treatment schedule. We are not able to show a difference in either remission duration or overall survival when comparing outcome of patients treated according to either the concurrent or the alternating imatinib schedule, however. It should be noted that our study was neither designed nor powered to detect such a difference, particularly in view of the overriding impact of subsequent stem cell transplantation in 80-85% of enrolled patients. Conspicuously, our results are inferior to those reported by Towatari et al. 24 and by Lee et al., 31 , even though both of these groups employed a strategy of combined imatinib and chemotherapy that was similar to ours, with transplantation rates in CR1 of 63% and 82%. One potentially crucial difference between our and their studies is patient age, with a rather high median age of 41 years and 46 years in our treatment cohorts compared to 36 years in the study reported by Lee et al.. 31 Additional differences may be donor selection, degree of HLA matching and center effects when comparing results from single or few transplant centers with those obtained in a multicenter setting such as in our patients.
While we did not compare treatment outcome in our study with the results of a historical control group, the probability of survival in Ph+ALL patients treated in 2 previous German Multicenter Trials of Adult ALL including stem cell transplantation was 15% at 3 years.
who were eligible for SCT and had a donor was 37%; the estimated incidence of relapse was 50% at 3 years and of death in CR 24% at 2 years. 4 Taken together, available data do not suggest that administration of imatinib as part of front-line treatment has a detrimental effect on overall or post-transplant treatment outcome.
Meanwhile, our study strongly suggests that schedules based on the simultaneous administration of imatinib and cytotoxic agents should form the basis for prospective, comparative studies aimed at improving the pre-transplant molecular response during first-line treatment of Ph+ALL. (21) 14 (31) n.a. 0 3 (7) lymphoid blast crisis 4 (9) 0 CR1, first complete remission; PR, partial remission ; n.a., not available; * With the alternating schedule, patients were enrolled after INDII if they had achieved a remission in response to induction chemotherapy; with the concurrent administration schedule, patients already entered the study after INDI, irrespective of their response to chemotherapy.
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